ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 199 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $223,000 | -81.0% | 3,614 | -73.7% | 0.00% | – |
| Q3 2018 | $1,174,000 | -53.7% | 13,745 | -37.2% | 0.00% | -100.0% |
| Q2 2018 | $2,536,000 | +104.5% | 21,875 | +42.6% | 0.00% | – |
| Q1 2018 | $1,240,000 | +88.4% | 15,336 | +36.7% | 0.00% | – |
| Q4 2017 | $658,000 | -36.9% | 11,221 | -66.9% | 0.00% | – |
| Q1 2017 | $1,043,000 | -27.4% | 33,872 | -21.0% | 0.00% | – |
| Q4 2016 | $1,437,000 | +42.3% | 42,878 | +13.0% | 0.00% | – |
| Q3 2016 | $1,010,000 | -56.8% | 37,957 | -64.2% | 0.00% | -100.0% |
| Q2 2016 | $2,336,000 | -4.2% | 105,942 | +27.6% | 0.00% | 0.0% |
| Q1 2016 | $2,438,000 | +137.2% | 83,016 | +166.6% | 0.00% | – |
| Q4 2015 | $1,028,000 | -1.2% | 31,136 | -8.4% | 0.00% | – |
| Q1 2015 | $1,040,000 | +152.4% | 33,973 | +319.4% | 0.00% | – |
| Q4 2014 | $412,000 | -94.5% | 8,100 | -97.5% | 0.00% | -100.0% |
| Q3 2013 | $7,432,000 | +23.9% | 324,291 | -4.3% | 0.00% | 0.0% |
| Q2 2013 | $5,999,000 | – | 338,791 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 1,546,097 | $66,590,000 | 9.91% |
| RA Capital Management | 1,539,586 | $66,310,000 | 6.70% |
| SENZAR ASSET MANAGEMENT, LLC | 255,128 | $10,988,000 | 4.20% |
| INSIGHT CAPITAL RESEARCH & MANAGEMENT INC | 158,315 | $6,819,000 | 1.56% |
| Sarissa Capital Management LP | 105,000 | $4,522,000 | 1.54% |
| Ghost Tree Capital, LLC | 50,000 | $2,154,000 | 1.52% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 118,445 | $5,102,000 | 0.90% |
| WALL STREET ASSOCIATES | 219,200 | $9,441,000 | 0.81% |
| Granite Point Capital Management, L.P. | 25,000 | $1,077,000 | 0.74% |
| BAILARD, INC. | 91,500 | $3,941,000 | 0.61% |